Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles

References

• O'Driscoll L. Expanding on exosomes and ectosomes in cancer. N Engl J Med. 2015;372(24):2359-62. doi:10.1056/NEJMcibr1503100. PMID:26061842
   PubMed Web of Science ®Google Scholar
• Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, Sheikh R, Webb G, McDermott R, Watson W, Crown J, O'Driscoll L. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One. 2012;7(12):e50999. doi:10.1371/journal.pone.0050999. PMID:23251413
   PubMed Web of Science ®Google Scholar
• O'Brien K, Lowry MC, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RA, O'Driscoll L. Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. Eur J Cancer. 2013;49(8):1845-59. doi:10.1016/j.ejca.2013.01.017
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707-12. doi:10.1126/science.2470152. PMID:2470152
   PubMed Web of Science ®Google Scholar
• Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene. 2007;26(25):3637-43. doi:10.1038/sj.onc.1210379. PMID:17530017
   PubMed Web of Science ®Google Scholar
• Arribas J, Baselga J, Pedersen K, Parra-Palau JL. p95HER2 and breast cancer. Cancer Res. 2011;71(5):1515-9. doi:10.1158/0008-5472.CAN-10-3795. PMID:21343397
   PubMed Web of Science ®Google Scholar
• Bruttel VS, Wischhusen J. Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape? Front Immunol. 2014;5:360. doi:10.3389/fimmu.2014.00360. PMID:25120546
   PubMed Web of Science ®Google Scholar
• Altevogt P, Bretz NP, Ridinger J, Utikal J, Umansky V. Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation. Semin Cancer Biol. 2014;28:51-7. doi:10.1016/j.semcancer.2014.04.008
   PubMed Web of Science ®Google Scholar
• Clayton A, Mitchell JP, Court J, Mason MD, Tabi Z. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res. 2007;67(15):7458-66. doi:10.1158/0008-5472.CAN-06-3456. PMID:17671216
   PubMed Web of Science ®Google Scholar
• Rong L, Li R, Li S, Luo R. Immunosuppression of breast cancer cells mediated by transforming growth factor-beta in exosomes from cancer cells. Oncol Lett. 2016;11(1):500-4. PMID:26870240
   PubMed Web of Science ®Google Scholar
• Mitchell JD, Maguire JJ, Davenport AP. Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S. Br J Pharmacol. 2009;158(1):87-103. doi:10.1111/j.1476-5381.2009.00252.x. PMID:19519756
   PubMed Web of Science ®Google Scholar
• Martinez VG, O'Driscoll L. Neuromedin U: a multifunctional neuropeptide with pleiotropic roles. Clin Chem. 2015;61(3):471-82. doi:10.1373/clinchem.2014.231753. PMID:25605682
   PubMed Web of Science ®Google Scholar
• Rani S, Corcoran C, Shiels L, Germano S, Breslin S, Madden S, McDermott MS, Browne BC, O'Donovan N, Crown J, et al. Neuromedin U: A Candidate Biomarker and Therapeutic Target to Predict and Overcome Resistance to HER-Tyrosine Kinase Inhibitors. Cancer Res. 2014;74(14):3821-33. doi:10.1158/0008-5472.CAN-13-2053. PMID:24876102
   PubMed Web of Science ®Google Scholar
• Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, Quraishi AA, Tawakkol N, D'Angelo R, Paulson AK, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell. 2012;47(4):570-84. doi:10.1016/j.molcel.2012.06.014
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871-90. doi:10.1016/j.cell.2009.11.007
   PubMed Web of Science ®Google Scholar
• Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147(2):275-92. doi:10.1016/j.cell.2011.09.024
   PubMed Web of Science ®Google Scholar
• Brabletz T. EMT and MET in metastasis: where are the cancer stem cells? Cancer Cell. 2012;22(6):699-701. doi:10.1016/j.ccr.2012.11.009
   PubMed Web of Science ®Google Scholar
• A Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P, Squarcina P, Accornero P, Lozupone F, Lugini L, et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med. 2002;195(10):1303-16. doi:10.1084/jem.20011624. PMID:12021310
   PubMed Web of Science ®Google Scholar
• Abusamra AJ, Zhong Z, Zheng X, Li M, Ichim TE, Chin JL, Min WP. Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol Dis. 2005;35(2):169-73. doi:10.1016/j.bcmd.2005.07.001. PMID:16081306
   PubMed Web of Science ®Google Scholar
• Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res. 2005;11(3):1010-20. PMID:15709166
   PubMed Web of Science ®Google Scholar
• Taylor DD, Gercel-Taylor C, Lyons KS, Stanson J, Whiteside TL. T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res. 2003;9(14):5113-9. PMID:14613988
   PubMed Web of Science ®Google Scholar
• Wen SW, Sceneay J, Lima LG, Wong CS, Becker M, Krumeich S, et al. The Biodistribution and Immune Suppressive Effects of Breast Cancer-Derived Exosomes. Cancer Res. 2016;76(23):6816-27. doi:10.1158/0008-5472.CAN-16-0868. PMID:27760789
   PubMed Web of Science ®Google Scholar
• Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, Rubinstein E, Le Moulec S, Guigay J, Hirashima M, Guemira F, et al. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood. 2009;113(9):1957-66. doi:10.1182/blood-2008-02-142596. PMID:19005181
   PubMed Web of Science ®Google Scholar
• Wieckowski EU, Visus C, Szajnik M, Szczepanski MJ, Storkus WJ, Whiteside TL. Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol. 2009;183(6):3720-30. doi:10.4049/jimmunol.0900970. PMID:19692638
   PubMed Web of Science ®Google Scholar
• Szajnik M, Czystowska M, Szczepanski MJ, Mandapathil M, Whiteside TL. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One. 2010;5(7):e11469. doi:10.1371/journal.pone.0011469. PMID:20661468
   PubMed Web of Science ®Google Scholar
• Clayton A, Tabi Z. Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol Dis. 2005;34(3):206-13. doi:10.1016/j.bcmd.2005.03.003. PMID:15885603.
   PubMed Web of Science ®Google Scholar
• Liu C, Yu S, Zinn K, Wang J, Zhang L, Jia Y, Kappes JC, Barnes S, Kimberly RP, Grizzle WE, et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol. 2006;176(3):1375-85. doi:10.4049/jimmunol.176.3.1375. PMID:16424164
   PubMed Web of Science ®Google Scholar
• Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, Villa A, Corbelli A, Fais S, Parmiani G, Rivoltini L.. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res. 2006;66(18):9290-8. doi:10.1158/0008-5472.CAN-06-1819. PMID:16982774
   PubMed Web of Science ®Google Scholar
• Liu Y, Xiang X, Zhuang X, Zhang S, Liu C, Cheng Z, Michalek S, Grizzle W, Zhang HG. Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells. Am J Pathol. 2010;176(5):2490-9. doi:10.2353/ajpath.2010.090777. PMID:20348242
   PubMed Web of Science ®Google Scholar
• Xiang X, Poliakov A, Liu C, Liu Y, Deng ZB, Wang J, Cheng Z, Shah SV, Wang GJ, Zhang L, et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer. 2009;124(11):2621-33. doi:10.1002/ijc.24249. PMID:19235923
   PubMed Web of Science ®Google Scholar
• Marton A, Vizler C, Kusz E, Temesfoi V, Szathmary Z, Nagy K, Szegletes Z, Varo G, Siklos L, Katona RL, et al. Melanoma cell-derived exosomes alter macrophage and dendritic cell functions in vitro. Immunol Lett. 2012;148(1):34-8. doi:10.1016/j.imlet.2012.07.006
   PubMed Web of Science ®Google Scholar
• Martinez VG, Crown J, Porter RK, O'Driscoll L. Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer. Int J Cancer. 2017;140(12):2771-2784. doi:10.1002/ijc.30705
   PubMed Web of Science ®Google Scholar
• Abdullah LN, Chow EK. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med. 2013;2(1):3. doi:10.1186/2001-1326-2-3. PMID:23369605
   PubMedGoogle Scholar
• Schatton T, Frank MH. Antitumor immunity and cancer stem cells. Ann N Y Acad Sci. 2009;1176:154-69. doi:10.1111/j.1749-6632.2009.04568.x. PMID:19796244
   PubMed Web of Science ®Google Scholar
• Codony-Servat J, Rosell R. Cancer stem cells and immunoresistance: clinical implications and solutions. Transl Lung Cancer Res. 2015;4(6):689-703. doi:10.3978/j.issn.2218-6751.2015.12.11
   PubMedGoogle Scholar
• Graner MW, Alzate O, Dechkovskaia AM, Keene JD, Sampson JH, Mitchell DA, Bigner DD. Proteomic and immunologic analyses of brain tumor exosomes. FASEB J. 2009;23(5):1541-1557. doi:10.1096/fj.08-122184. PMID:19109410
   PubMed Web of Science ®Google Scholar
• Hong CS, Muller L, Whiteside TL, Boyiadzis M. Plasma exosomes as markers of therapeutic response in patients with acute myeloid leukemia. Front Immunol. 2014;5:160. eCollection 2014. doi:10.3389/fimmu.2014.00160. PMID:24782865
   PubMed Web of Science ®Google Scholar
• Breslin S, Lowry MC, O'Driscoll L. Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4. Br J Cancer. 2017;116(5):620-625. doi:10.1038/bjc.2016.445. PMID:28152547.
   PubMed Web of Science ®Google Scholar
• Mitchell JP, Court J, Mason MD, Tabi Z, Clayton A. Increased exosome production from tumour cell cultures using the Integra CELLine Culture System. J Immunol Methods. 2008;335(1-2):98-105. doi:10.1016/j.jim.2008.03.001
   PubMed Web of Science ®Google Scholar
• Lötvall J, Hill AF, Hochberg F, Buzás EI, Di Vizio D, Gardiner C, Gho YS, Kurochkin IV, Mathivanan S, Quesenberry P, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles. 2014;3:26913. doi:10.3402/jev.v3.26913. PMID:25536934
   PubMedGoogle Scholar